Please login to the form below

Not currently logged in
Email:
Password:

anti-inflammatory

This page shows the latest anti-inflammatory news and features for those working in and with pharma, biotech and healthcare.

Novartis culls pipeline to focus on most transformative science

Novartis culls pipeline to focus on most transformative science

Anti-infectives among areas hit by streamlining. Novartis has revealed that it is to abandon over 100 R&D programmes, slashing its pipeline by a fifth. ... It recently hit problems with one of its most important late-stage programmes when the FDA refused

Latest news

More from news
Approximately 1 fully matching, plus 121 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2015 Deal Watch October 2015

    Under the agreement Janssen has an option to license enGene's lead candidate, EG-12, for the gut-localised expression of the anti-inflammatory cytokine IL-10 in indications such as ... Up to 3 anti-PD-1 based bispecific antibodies for oncology. Expansion

  • Pharma deals during December 2014 Pharma deals during December 2014

    J&J has been busy entering into licences and research collaborations on the one hand, while exercising an opt-out and terminating its $945m anti-inflammatory deal with Astellas that was ... In early December, Merck added more weight to its

  • Investing in the future of R&D Investing in the future of R&D

    The anti-inflammatory TNF drug, whose indications currently include rheumatoid arthritis and Crohn's disease, became UCB's leading product in the first half of 2014, thanks to 23% growth in ... This was followed in March by a drug discovery and

  • Back to the future Back to the future

    The best-selling biologic - and still pharma's biggest global brand - is Humira, AbbVie and Eisai's anti-inflammatory drug.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    167. UCB/ Sanofi. Collaboration - discovery/ development. Anti-inflammatory small molecules for treatment of immune-mediated disorders (discovery). ... Genmab/ Janssen. Milestone payment. Daratumumab, anti-CD38 mAb for multiple myeloma (p2 milestone).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics